Mustang Bio AI Stock Analysis
Want to see MBIO full AI Analyst Report?
Mustang Bio (MBIO) AI Stock Analysis
Mustang Bio
(NASDAQ:MBIO)
Mustang Bio's score is driven primarily by its weak financial performance as a pre-revenue biotech with persistent losses, despite improvements in cost control and a debt-free balance sheet. The stock is in a clear downtrend with bearish technicals, and traditional valuation metrics offer no support. While the company has made strides toward financial stability, significant uncertainty remains, resulting in a low overall score.
Mustang Bio (MBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 32.28K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.76
- Revenue Growth
- ―
- EPS Growth
- 59.14%
- Country
- US
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Mustang Bio Business Overview & Revenue Model
Company Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen...
How the Company Makes Money
Mustang Bio is a clinical-stage company and, as such, does not have a broadly established, recurring product-revenue base from commercialized therapies. The company has historically funded operations primarily through capital raising (e.g., equity fi...
Mustang Bio Financial Statement Overview
Summary
Mustang Bio has no revenue and continues to report net losses, though losses have narrowed significantly. The balance sheet is debt-free with positive equity, providing a modest cushion. Operating cash flow remains negative but improving. Overall financial health is weak but showing progress, typical of a developmental-stage biotech.
Income Statement
30NegativeBalance Sheet
65PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -41.00K | 0 | -2.23M | -3.03M | -2.31M |
| EBITDA | -3.53M | -1.88M | -14.92M | -48.06M | -71.14M | -64.05M |
| Net Income | -3.53M | -1.92M | -15.75M | -51.60M | -77.53M | -66.37M |
Balance Sheet | ||||||
| Total Assets | 14.68M | 17.59M | 9.31M | 17.74M | 92.42M | 125.17M |
| Cash, Cash Equivalents and Short-Term Investments | 14.28M | 17.27M | 6.84M | 6.23M | 75.66M | 109.62M |
| Total Debt | 0 | 0 | 878.00K | 2.50M | 31.38M | 2.03M |
| Total Liabilities | 8.10M | 8.06M | 13.18M | 17.62M | 46.15M | 12.77M |
| Stockholders Equity | 6.59M | 9.53M | -3.87M | 123.00K | 46.27M | 112.40M |
Cash Flow | ||||||
| Free Cash Flow | -4.57M | -5.26M | -11.41M | -49.59M | -68.14M | -59.03M |
| Operating Cash Flow | -4.57M | -5.26M | -11.41M | -49.48M | -65.07M | -53.67M |
| Investing Cash Flow | 0 | 1.17M | 0 | 5.89M | -2.95M | -5.37M |
| Financing Cash Flow | -139.00K | 14.53M | 11.27M | -26.08M | 34.06M | 70.85M |
Mustang Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Neutral. The current price of 0.42 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.44, and below the 200-day MA of 0.66, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.54 is Neutral, neither overbought nor oversold. The STOCH value of 51.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MBIO.
Mustang Bio Risk Analysis
Mustang Bio disclosed 65 risk factors in its most recent earnings report. Mustang Bio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksMustang Bio Peers Comparison
Overall Rating
BOLT47Neutral
ACXP45Neutral
LYRA41Neutral
SLXN41Neutral
MBIO40Underperform
XTLB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $11.71M | -0.42 | -154.11% | ― | -51.28% | 32.80% | |
| 45Neutral | $5.82M | -0.34 | -116.60% | ― | ― | 72.95% | |
| 41Neutral | $337.23K | -0.01 | 455.31% | ― | -74.05% | 73.08% | |
| 41Neutral | $1.29M | -0.00 | -895.97% | ― | ― | 36.44% | |
| 40Underperform | $3.20M | -0.82 | -43.76% | ― | ― | 59.14% | |
| 39Underperform | $7.81M | -0.54 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MBIO | Mustang Bio | 0.42 | -0.74 | -63.71% | |
| XTLB | XTL Biopharmaceuticals Ltd. Sponsored ADR | 1.60 | -2.04 | -56.04% | |
| LYRA | Lyra Therapeutics, Inc. | 0.19 | -3.55 | -94.92% | |
| BOLT | Bolt Biotherapeutics, Inc. | 6.08 | 1.57 | 34.81% | |
| SLXN | Silexion Therapeutics Corp | 1.98 | -617.22 | -99.68% | |
| ACXP | Acurx Pharmaceuticals Llc | 0.96 | -3.26 | -77.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 09, 2026
